Dr. Weber is Deputy Director at the Laura and Isaac Perlmutter Cancer Center at the NYU Langone Medical Center, is a Professor of Medicine at NYU, and Head of Experimental Therapeutics at the Perlmutter Cancer Center. He is a translational clinician-scientist and clinical trialist with an interest in immuno-oncology and the development of new treatment strategies for patients with melanoma.
Dr. Weber has been funded by the National Cancer Institute with RO1 funding for over 20 years and was the principal investigator of the Moffitt Skin SPORE, a large multi-project grant thatis funded by the National Institutes of Health. He has sat on numerous study sections and has been instrumental in the development of the three immuno-oncology agents that have been approved by the FDA in the last four years: ipilimumab, nivolumab, and pembrolizumab.
Dr. Weber was the first to show, and was the principal investigator of the first trial that demonstrated benefit for PD-1 blocking antibodies in melanoma patients that had failed ipilimumab. He was also the first investigator who demonstrated that PD-1 blocking antibodies had encouraging activity in resected melanoma patients and is the international principal investigator of the first adjuvant trial of PD-1 blocking antibody nivolumab in patients with surgically resected melanoma at high risk or recurrence. Dr. Weber maintains an active portfolio of clinical trials and runs a laboratory effort in which tumor and blood samples are analyzed for markers that are associated with benefit from novel immuno-oncology agents.
Dr. Weber has disclosed that he is a consultant for AbbVie, Altor, AstraZeneca, Bristol-Myers Squibb, cCAM, Celldex, CytoMx, EMD Serono, Genentech/Roche, GlaxoSmithKline, Merck, and Nektar. He also receives grant/research support from Altor, cCAM, Celldex, and CytoMx.